about
Is chest X-ray screening for lung cancer in smokers cost-effective? Evidence from a population-based study in Italy.Late-stage pharmaceutical R&D and pricing policies under two-stage regulation.Two-part payments for the reimbursement of investments in health technologies.Should current criteria for detecting and repairing arteriovenous fistula stenosis be reconsidered? Interim analysis of a randomized controlled trial.Static and dynamic efficiency of irreversible health care investments under alternative payment rulesAn extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomographyAuthors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition"Job sick leave: Detecting opportunistic behaviorValue-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and CompetitionWhich valued-based price when patients are heterogeneous?
P50
Q36053946-73620F4D-7807-4D5C-A92A-E54E6A538A06Q39253732-7D03B68E-77AC-466B-A2D8-7CFE6A332DF5Q46469024-0D5FF66C-2149-4B6C-9F00-AD7E150115DEQ48919269-06240393-C888-4C33-8B7A-B211E3297833Q82145767-0AA39522-384C-4C29-A35A-FBC29CD1ED66Q83201138-9B0D368B-3164-4156-9A6F-AC1E7E8D847FQ89523642-718558BF-D8FA-4412-8DD7-35D3DBEE0BDCQ90617086-D654F433-8FFF-497E-B993-D4CBF3EF0831Q91589934-05F5BABD-BBC1-4857-AA32-00B38BA918E5Q96348245-D4D2FC8F-A3D2-4540-92A6-C7B262B0BC97
P50
description
investigador
@es
researcher
@en
name
P Pertile
@en
type
label
P Pertile
@en
prefLabel
P Pertile
@en
P31
P496
0000-0002-6555-5491